[go: up one dir, main page]

WO2000031279A3 - Producing antimicrobial cationic peptides as fusion proteins - Google Patents

Producing antimicrobial cationic peptides as fusion proteins Download PDF

Info

Publication number
WO2000031279A3
WO2000031279A3 PCT/CA1999/001107 CA9901107W WO0031279A3 WO 2000031279 A3 WO2000031279 A3 WO 2000031279A3 CA 9901107 W CA9901107 W CA 9901107W WO 0031279 A3 WO0031279 A3 WO 0031279A3
Authority
WO
WIPO (PCT)
Prior art keywords
cationic peptides
cationic
peptides
fusion proteins
antimicrobial cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/001107
Other languages
French (fr)
Other versions
WO2000031279A2 (en
Inventor
Jan Burian
Daniel Bartfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biowest Therapeutics Inc
Original Assignee
Micrologix Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micrologix Biotech Inc filed Critical Micrologix Biotech Inc
Priority to HK02101246.8A priority Critical patent/HK1040737A1/en
Priority to EP99955614A priority patent/EP1131448A2/en
Priority to JP2000584088A priority patent/JP2002530114A/en
Priority to AU12553/00A priority patent/AU1255300A/en
Priority to CA002351737A priority patent/CA2351737A1/en
Publication of WO2000031279A2 publication Critical patent/WO2000031279A2/en
Publication of WO2000031279A3 publication Critical patent/WO2000031279A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means to efficiently produce cationic peptides from recombinant host cells. These recombinantly-produced cationic peptides can be rapidly purified from host cell proteins using anion exchange chromatography.
PCT/CA1999/001107 1998-11-20 1999-11-19 Producing antimicrobial cationic peptides as fusion proteins Ceased WO2000031279A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HK02101246.8A HK1040737A1 (en) 1998-11-20 1999-11-19 Producing antimicrobial cationic peptides as fusion proteins
EP99955614A EP1131448A2 (en) 1998-11-20 1999-11-19 Producing antimicrobial cationic peptides as fusion proteins
JP2000584088A JP2002530114A (en) 1998-11-20 1999-11-19 Efficient method for producing antimicrobial cationic peptides in host cells
AU12553/00A AU1255300A (en) 1998-11-20 1999-11-19 Efficient methods for producing antimicrobial cationic peptides in host cells
CA002351737A CA2351737A1 (en) 1998-11-20 1999-11-19 Efficient methods for producing antimicrobial cationic peptides in host cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10921898P 1998-11-20 1998-11-20
US60/109,218 1998-11-20

Publications (2)

Publication Number Publication Date
WO2000031279A2 WO2000031279A2 (en) 2000-06-02
WO2000031279A3 true WO2000031279A3 (en) 2000-10-19

Family

ID=22326442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/001107 Ceased WO2000031279A2 (en) 1998-11-20 1999-11-19 Producing antimicrobial cationic peptides as fusion proteins

Country Status (6)

Country Link
EP (1) EP1131448A2 (en)
JP (1) JP2002530114A (en)
AU (1) AU1255300A (en)
CA (1) CA2351737A1 (en)
HK (1) HK1040737A1 (en)
WO (1) WO2000031279A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538828A (en) * 1999-03-17 2002-11-19 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション Transgenic plants resistant to broad-spectrum pathogens
US6835868B1 (en) 1999-03-17 2004-12-28 University Of Victoria Innovation And Development Corporation Transgenic plants expressing dermaseptin peptides providing broad spectrum resistance to pathogens
ES2525317T3 (en) 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Recombinant production of peptide antiviral fusion inhibitors
US20030219402A1 (en) * 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
AU2003228637B2 (en) 2002-04-22 2010-08-05 Dow Global Technologies Inc. Low-cost production of peptides
JP2008054673A (en) * 2006-08-03 2008-03-13 Hokkaido Univ Method for producing recombinant protein
AU2010255732B8 (en) * 2009-06-03 2014-03-13 Basf Se Recombinant production of peptides
KR101286733B1 (en) * 2010-12-06 2013-07-16 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 Multimeric antimicrobial peptide expressed on cell surface
US20140315789A1 (en) * 2011-11-23 2014-10-23 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
CN103352046A (en) * 2013-05-23 2013-10-16 甘肃智信达生物科技有限公司 Expression and enlarged culture of Apidaecin type antibacterial peptide in Pichia yeast

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028559A1 (en) * 1995-03-13 1996-09-19 University Of British Columbia Method for the production of cationic peptides
WO1998054336A1 (en) * 1997-05-28 1998-12-03 Samyang Genex Corporation Method for mass production of antimicrobial peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028559A1 (en) * 1995-03-13 1996-09-19 University Of British Columbia Method for the production of cationic peptides
WO1998054336A1 (en) * 1997-05-28 1998-12-03 Samyang Genex Corporation Method for mass production of antimicrobial peptide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASTEELS-JOSSON KATTY ET AL: "Apidaecin multipeptide precursor structure: A putative mechanism for amplification of the insect antibacterial response.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 12, no. 4, 1993, pages 1569 - 1578, XP002141022, ISSN: 0261-4189 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1999 (1999-06-01), LEE JAE-HYUN ET AL: "Multimeric expression of the antimicrobial peptide buforin II in Escherichia coli by fusion to a cysteine-rich acidic peptide.", XP002141023, Database accession no. PREV199900402580 *
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 9, no. 3, June 1999 (1999-06-01), pages 303 - 310, ISSN: 1017-7825 *
LEE JAE H ET AL: "Acidic peptide-mediated expression of the antimicrobial peptide buforin II as tandem repeats in Escherichia coli.", PROTEIN EXPRESSION AND PURIFICATION, vol. 12, no. 1, February 1998 (1998-02-01), pages 53 - 60, XP000914932, ISSN: 1046-5928 *
ZHANG L ET AL: "Determinants of recombinant production of antimicrobial cationic peptides and creation of peptide variants in bacteria.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1998 JUN 29) 247 (3) 674-80., XP002141021 *

Also Published As

Publication number Publication date
CA2351737A1 (en) 2000-06-02
JP2002530114A (en) 2002-09-17
AU1255300A (en) 2000-06-13
WO2000031279A2 (en) 2000-06-02
HK1040737A1 (en) 2002-06-21
EP1131448A2 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
ATE336586T1 (en) OIL-BODY PROTEINS AS CARRIERS OF HIGH-QUALITY PEPTIDES IN PLANTS
WO2000031279A3 (en) Producing antimicrobial cationic peptides as fusion proteins
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
DE69900746D1 (en) CONTROLLED ADMINISTRATION OF PEPTIDES OR PROTEINS
DE3689246D1 (en) Physiologically active polypeptide BUF-3.
AU3273100A (en) Ion exchange chromatography of proteins and peptides with an organic modifier in the elution step
IT8520242A0 (en) PHYSIOLOGICALLY ACTIVE HUMAN POLYPEPTIDE.
SI0866876T1 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
AU2001278797A1 (en) Expression vector using for animal cell
BR9813692B1 (en) process for producing a recombinant pestivirus protein e2 vaccine in insect cell culture, and e2 subunit vaccine.
FI971613A7 (en) Defective adenoviruses comprising a therapeutic gene and an immunoprotective gene
DK1394179T3 (en) Process for the preparation of erythropoietin free of animal proteins
DK1011653T3 (en) Use of xanthophylls in medications to improve the duration of muscle function or treatment of muscle disorders or disorders
ATE404583T1 (en) FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY
DK0936902T3 (en) Spray-dried microparticles as therapeutic carriers for use in therapy
DE69132708D1 (en) Therapeutic use of peptides with thrombospondin-like activity
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
AU4218389A (en) Peptide compounds
CA2191750A1 (en) Virosome-mediated intracellular delivery of therapeutic agents
WO1994003601A8 (en) Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
CA2306820A1 (en) Improved methods for producing factor viii proteins
ATE346096T1 (en) G-CSF TPO FUSION PROTEINS
EA199900750A1 (en) AQUEOUS PHARMACEUTICAL COMPOSITION, INCLUDING THE ACTIVE INGREDIENT, IN THE HIGHEST DEGREE IN THE WATER
FI956352A0 (en) Protein S deletion variants lacking C4BP binding activity but having APC cofactor activity in compositions and therapeutic methods
NO902248L (en) PURE-INHIBITING PEPTIDES, THEIR PREPARATION AND USE IN PHARMACEUTICALS.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 12553

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2351737

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 2000 584088

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999955614

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999955614

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642